News
New clinical trials are advancing treatments for cutaneous T-cell lymphoma, advanced solid tumors, pediatric sarcomas and ALK ...
The ALKAZAR trial is designed to enroll ~450 TKI-naïve patients with advanced ALK-positive NSCLC. Patients will be randomized ...
Frequent and permanent night shift work is associated with increased lung cancer risk with smoking being a significant factor.
A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.
Panelists discuss how a 48-year-old fitness instructor with ALK-rearranged stage IV lung cancer and bone metastases was ...
If you thought only smokers get lung cancer think again here’s what could be silently putting non-smokers at risk ...
During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...
Many lung cancers in nonsmokers have no known cause and are discovered only by chance.
Scientists have uncovered a molecular "on–off" switch that helps lung adenocarcinoma—the most common form of lung cancer—grow ...
The study will compare neladalkib to Genentech's ALK inhibitor Alecensa in patients who've had no prior systemic treatment.
(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the first patient has ...
They want to gain a deeper understanding of why the disease behaves differently in these patients. Read more at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results